Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2014

View Archived Issues

VU-0453595 shows potential for schizophrenia in a mouse model

Preliminary data on safety and efficacy of ALD-403 for the prevention of migraine

Protagen and Qiagen to develop protein-based companion diagnostics for autoimmune drugs

Maruho announces results of the phase III study of M-8010 for the treatment of psoriasis vulgaris

Theravectys updates on phase I/II trial of lentiviral vector HIV vaccine

Intellia Therapeutics closes financing to develop ex vivo gene therapies using CRISPR-Cas9 system

Preclinical data for an orally active opioid analgesic, SEO-16

Clinical benefit on rheumatoid arthritis demonstrated in phase I trial of FPA-008

Preliminary results of a phase II study comparing AQ-13 to coartemether

CYP7A1 inhibitor NGM-282: results of first phase I trial

Aldoxorubicin clinical trials placed on partial clinical hold

Spinal muscular atrophy program enters phase Ib/IIa trial

Health Canada clears Immunovaccine to conduct phase II trial of DPX-Survivac

Kissei Pharmaceutical submits NDA in Japan for PA-21

FDA grants orphan drug designation to Cabaletta for SCA3

Merrimack Pharmaceuticals receives FDA fast track designation for MM-398

Synergy Pharmaceuticals reports data from phase II SP-333 trial

Ajinomoto discloses new GS activators for diabetes

Merck & Co. patents novel MAPK 1 inhibitors for cancer

Vitae Pharmaceuticals patent reports new RORgamma inverse agonists

Janssen files NDA for 3-month formulation of paliperidone palmitate for schizophrenia

New compounds for bacterial infections designed by Neoculi

BerGenBio's BGB-324 receives FDA orphan drug designation

FDA awards breakthrough therapy designation to dupilumab for atopic dermatitis

Janssen files MAA for Simponi in severe active non-radiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...